Celldom Lands $938K Phase II SBIR Grant From NCI
NEW YORK – Cell analysis firm Celldom said Tuesday that it has won a $938,647 Phase II Small Business Innovation Research grant from the National Cancer Institute. In an email, CEO and Cofounder Ben Yellen said the grant will fund development of an application of its instrument for chimeric antigen receptor T-cell (CAR T-cell) potency testing. “We can perform a complete lot release assay with just a few thousand cells, which enables CAR T to be administered without needing to expand the cells ex vivo,” he said. Celldom’s instrument combines imaging-based phenotyping with molecular profiling. The grant is the third SBIR award for San Carlos, California-based Celldom, a Duke University spinout.
